grant

EBV-specific T cells as therapy for relapsed - refractory EBV-positive lymphomas [ 2009 - 2011 ]

Also known as: Adoptive Immunotherapy for Lymphoma

Research Grant

[Cite as https://purl.org/au-research/grants/nhmrc/552469]

Researchers: Prof Maher Gandhi (Principal investigator) ,  Prof David Ritchie

Brief description The presence of Epstein-Barr virus (EBV) withiin EBV-positive malignant lymphoma cases provides a potential target for adoptive immunotherapy. Previous studies have established that adoptive immunotherapy for certain subtypes of lymphoma with EBV-specific killer T cells can lead to remission of disease. The objective of this study is to examine whether a similar strategy but using an enhanced methodology can be applied for the treatment of a range of relapsed-refractory EBV-positive lymphomas.

Funding Amount $AUD 324,397.29

Funding Scheme NHMRC Project Grants

Notes Standard Project Grant

Click to explore relationships graph
Identifiers
Viewed: [[ro.stat.viewed]]